Adjuvant and neoadjuvant therapy in curable pancreatic cancer.

[1]  Chronic Disease Division.  Cancer facts and figures , 2010 .

[2]  H. Ueno,et al.  A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer , 2009, British Journal of Cancer.

[3]  D. Smith,et al.  ESPAC-3(v2): A multicenter, international, open-label, randomized controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  B. Topal,et al.  Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[5]  J. Plastaras,et al.  Adjuvant radiotherapy for pancreatic cancer is associated with a survival benefit primarily in stage IIB patients , 2009, Journal of Gastroenterology.

[6]  K. Trinkaus,et al.  Adjuvant Interferon-based Chemoradiation Followed By Gemcitabine for Resected Pancreatic Adenocarcinoma: A Single-Institution Phase II Study , 2008, Annals of surgery.

[7]  Jeffrey E. Lee,et al.  Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Donohue,et al.  Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Jeffrey E. Lee,et al.  Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Abrams,et al.  ACOSOG Z05031: Report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5- FU, and alpha-interferon , 2008 .

[11]  H. Oettle,et al.  CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC) , 2008 .

[12]  C. Ko,et al.  Survival After Resection of Ampullary Carcinoma: A National Population-Based Study , 2008, Annals of Surgical Oncology.

[13]  W. Hop,et al.  Long-term Survival and Metastatic Pattern of Pancreatic and Periampullary Cancer After Adjuvant Chemoradiation or Observation: Long-term Results of EORTC Trial 40891 , 2007, Annals of surgery.

[14]  Peter Neuhaus,et al.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. , 2007, JAMA.

[15]  J. Cameron,et al.  146: Adjuvant Chemoradiation for Adenocarcinoma of the Pancreas: The Johns Hopkins Experience , 2006 .

[16]  W. Regine,et al.  On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer. , 2006, Annals of surgery.

[17]  R. Abrams,et al.  RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Yamamura,et al.  Surgical oncotaxis--excessive surgical stress and postoperative complications contribute to enhancing tumor metastasis, resulting in a poor prognosis for cancer patients. , 2005, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[19]  D. Tyler,et al.  Neoadjuvant therapy for pancreatic cancer: the Duke experience. , 2004, Surgical oncology clinics of North America.

[20]  Helen Hickey,et al.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. , 2004, The New England journal of medicine.

[21]  L. Traverso,et al.  Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. , 2003, American journal of surgery.

[22]  T. Takada,et al.  Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? , 2002, Cancer.

[23]  K. Lillemoe,et al.  Resected adenocarcinoma of the pancreas— 616 patients: Results, outcomes, and prognostic indicators , 2000, Journal of Gastrointestinal Surgery.

[24]  L. Traverso,et al.  Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. , 2000, American journal of surgery.

[25]  J. Jeekel,et al.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. , 1999, Annals of surgery.

[26]  R H Hruban,et al.  Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. , 1997, Annals of surgery.

[27]  Jeffrey E. Lee,et al.  Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  E. Vokes.  The promise of biochemical modulation in combined modality therapy. , 1994, Seminars in Oncology.

[29]  A. Andrén-sandberg,et al.  Recurrence of exocrine pancreatic cancer--local or hepatic? , 1993, Hepato-gastroenterology.

[30]  J. Paradelo,et al.  Patterns of failure after curative resection of pancreatic carcinoma , 1990, Cancer.

[31]  S. Wadler,et al.  Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. , 1990, Cancer research.

[32]  K. Cantell,et al.  Enhancement of radiation effects by alpha interferon in the treatment of small cell carcinoma of the lung. , 1987, International journal of radiation oncology, biology, physics.

[33]  S. Ellenberg,et al.  Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. , 1985, Archives of surgery.

[34]  J. Tepper,et al.  Carcinoma of the pancreas: Review of MGH experience from 1963 to 1973—Analysis of surgical failure and implications for radiation therapy , 1976, Cancer.

[35]  R. Weichselbaum,et al.  Adjuvant radiotherapy for resected pancreatic cancer: a lack of benefit or a lack of adequate trials? , 2009, Nature Clinical Practice Gastroenterology &Hepatology.

[36]  Yi-Jen Chen,et al.  Improved survival with adjuvant external‐beam radiation therapy in lymph node‐negative pancreatic cancer , 2008, Cancer.

[37]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[38]  S. Lipsitz,et al.  Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  B. Eisenberg,et al.  A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. , 1995, American journal of surgery.

[40]  C. Charnsangavej,et al.  Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. , 1994, American journal of surgery.

[41]  O. Dahl,et al.  Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater--results of a controlled, prospective, randomised multicentre study. , 1993, European journal of cancer.